Glucocorticoids (GC) are the mainstay of treatment of polymyalgia rheumatica (PMR). However GC-related adverse events occur frequently, particularly in patients with relapsing disease. Several studies have demonstrated that IL-6 is a key player in the pathogenesis of PMR.
Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature / Macchioni, Pierluigi; Boiardi, Luigi; Catanoso, Mariagrazia; Pulsatelli, Lia; Pipitone, Nicolò; Meliconi, Riccardo; Salvarani, Carlo. - In: SEMINARS IN ARTHRITIS AND RHEUMATISM. - ISSN 1532-866X. - 43:1(2013), pp. 113-118. [10.1016/j.semarthrit.2013.01.003]
Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature
SALVARANI, CARLO
2013
Abstract
Glucocorticoids (GC) are the mainstay of treatment of polymyalgia rheumatica (PMR). However GC-related adverse events occur frequently, particularly in patients with relapsing disease. Several studies have demonstrated that IL-6 is a key player in the pathogenesis of PMR.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
